FIELD: biochemistry.
SUBSTANCE: invention relates to antigen-binding protein for CD3 binding. Also disclosed is a polynucleotide encoding said protein, a pharmaceutical composition containing said antibody. Disclosed is a method of producing said antibody and using said polynucleotide or vector.
EFFECT: invention provides effective treatment of diseases associated with CD3.
11 cl, 1 ex, 1 tbl, 4 dwg
Title | Year | Author | Number |
---|---|---|---|
MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2753882C2 |
ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
INDUCIABLE BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2800034C2 |
ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
Authors
Dates
2021-02-09—Published
2015-08-05—Filed